TIANFU CHEM Pitavastatin calcium CAS NO.147526-32-7

product name: pitavastatin calcium
synonyms: pitavasttin calcium;pitavastatin calcium /nk-104;(+)-monocalciunbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl-3-quinolyl]-3,5-dihydroxy-6-heptenotate};pitavastatin calcium(livalo);calcium (3r,5s,e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoate;pitavastatin calcium discontinued;(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid,calcium salt (2:1);nk-104 calcium
cas: 147526-32-7
mf: c50h46caf2n2o8
mw: 880.98
einecs:
product categories: pharmaceuticals;chemical;api;livalo;cardiovascular series;active pharmaceutical ingredients;inhibitors;intermediates & fine chemicals
mol file: 147526-32-7.mol
pitavastatin calcium structure
pitavastatin calcium chemical properties
alpha d20 +23.1° (c = 1.00 in acetonitrile/water)
cas database reference 147526-32-7(cas database reference)
safety information
safety statements 24/25
msds information
pitavastatin calcium usage and synthesis
statin lipid-lowering drugs pitavastatin calcium is jointly developed by two companies nissan chemical and kowa co.it is the first total synthesis hmg-coa reductase inhibitor, it belongs to statin drugs ,it reduces the ability of the liver to manufacture cholesterol mainly through inhibition of some liver enzymes called hmgco-a reductase , thus it improves the elevated blood cholesterol levels, it is primarily used for the treatment of hypercholesterolemia and familial hypercholesterolemia patients,its lipid-lowering effect is very good, it is the most potent lipid-lowering drug so far.
pharmacological effects inhibition of hmg-coa reductase: pitavastatin calcium has a strongly antagonistic inhibition effect on hmg-coa enzyme , ic50 value is 6.8 nmol/l, and its intensity is 24 times of simvastatin, while it is 68 times of fluvastatin.
it hinders the synthesis of cholesterol: the ability to effectively inhibit the process of generating cholesterol in human hepatocytes hepg2 , ic50 value is 5.8nmol/l, and its intensity is 29 times of simvastatin, it is 57 times that of atorvastatin. but pitavastatin calcium inhibition effect on each enzyme in cholesterol generation after generation of mevalonate is very weak.
it increases ldl receptor density: pitavastatin induces the synthesis of lds receptor mrna in the ultra-low concentration of 1μmol/l, it can increase the number of lds receptor mrna , it results in the increasing of ldl receptor density , thereby it promotes clearance of ldl , so that plasma ldl-plasma total cholesterol concentration and triglyceride concentration decrease.
the above information is edited by the chemicalbook of tian ye.
pharmacokinetics the main parts of its absorption after oral administration are the duodenum and colon,its rate of binding plasma protein in the body is 96%and it is more selectively distributed in the liver after absorption , the drug concentration in body tissues is lower than that in the plasma or the same as that in the plasma . pitavastatin calcium is mainly metabolized in the liver, kidney, lung, heart, muscle , metabolite concentrations are lower than the concentration of drug prototype, it is excreted through feces,there is also a small amount of drug excretion through urine , total excretion rate is almost 100%.
a healthy male adult oral pitavastatin is 0.5~8mg, t1/2 is about 10h,the cmax and auc of the prototype drug in plasma increase with increasing dose , repeatedly taking does not result in medication savings.
toxicity acute toxicity: rats and dogs oral,study its acute toxicity. pitavastatin calcium median lethal dose on the rats are about male 500~1000mg/kg, female 250~500 mg/kg, dogs lethal dose is about 50~100mg/kg.
long term toxicity: respectively, rats, dogs and monkeys are administered a long-term experiment. from the experimental results, the safe dose of pitavastatin calcium are rats 1 mg/kg · d-1 (6 months), canine 0.3mg/kg · d-1 (12 months), monkey 3mg/kg · d-1 (6 months). no central nervous system, reproductive system, and myocardial dysfunction is observed which is common while taking other statins during administration.
carcinogenicity, mutagenicity: mouse oral 1,12,30, 75mg/kg dose, the incidence of cancer has no significant increase than in the control group .in chromosome abnormality tests, at the highest concentration of 625μg/ml,the result is positive, but at the same concentration, gene mutation recovery tests, micronucleus test s(in vivo) and uds test s(in vivo) are negative.